July 7, 2021. As organizations working to promote and protect science for the public good, we are writing to express our concern about the lack of scientific evidence to support the FDA’s recent accelerated approval of Biogen’s Aduhelm (aducanumab) as a drug intended to slow cognitive damage caused by Alzheimer’s disease.
Read More »On Medical Treatments & Products
NCHR’s Comments on AHRQ’s Draft Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain
June 14, 2021: Although we support the goals of the review and agree that there is a need for a systematic review of the effects of cannabis and other plant-based treatments for chronic pain, there are several important limitations of the report that were either not adequately addressed or were not mentioned.
Read More »NCHR’s Testimony to FDA on Pediatric Covid Vaccines
June 10, 2021: We agree with the FDA’s assessment that the lower burden of disease for COVID-19 in pediatric populations warrants more stringent criteria for safety and efficacy of vaccines than for adults.
Read More »Statement of Dr. Diana Zuckerman on FDA’s Approval of Alzheimer’s Drug Aduhelm
June 8, 2021: Dr. Diana Zuckerman, president of NCHR, speaks out against FDA’s approval of the ineffective Alzheimer’s drug aduhelm.
Read More »NCHR’s Statement to FDA Advisory Committee Meeting on Neurological Devices
June 3, 2021: We urge the FDA to regulate the neurological devices in question as Class II, and require the kind of meaningful evidence for new devices that we would want for any device that we use as health professionals, as patients, or as consumers.
Read More »